ANVS

Annovis Bio, Inc.

1.02

USD

0.00

0.00%

Oct 29, 15:59 UTC -4

Closed

After-Market

1.04

+0.02

+1.76%

Annovis Bio, Inc. (ANVS) Earnings

ANVS Earnings Reports

Positive Surprise Ratio

ANVS beat 11 of 23 last estimates.

48%

Next Report

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.37

Implied change from Q2 26 (Revenue/ EPS)

-7.50%

Implied change from Q3 25 (Revenue/ EPS)

Annovis Bio, Inc. earnings per share and revenue

On Aug 14, 2026, ANVS reported earnings of -0.40 USD per share (EPS) for Q2 26, beating the estimate of -0.46 USD, resulting in a 13.49% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.35% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 5 analysts forecast an EPS of -0.37 USD, with revenue projected to reach -- USD, implying an decrease of -7.50% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Gilead Sciences Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.24

Actual

$2.54

Surprise

+13.66%

Bristol-Myers Squibb Co.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.20

Actual

$1.35

Surprise

+11.66%

Illumina Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.38

Actual

$1.44

Surprise

+4.18%

Alnylam Pharmaceuticals, Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$1.65

Actual

$16.26

Surprise

+885.34%

Incyte Genomics Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$3.92

Actual

-$3.60

Surprise

+8.33%

Exelixis Inc

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.81

Actual

$0.94

Surprise

+15.64%

Kymera Therapeutics, Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$1.29

Actual

-$1.32

Surprise

-2.17%

Ligand Pharmaceuticals Inc.

Report Date

Oct 29, 2026 For Q3 26

Estimate

$2.42

Actual

$2.67

Surprise

+9.91%

Fortrea Holdings Inc. Common Stock

Report Date

Oct 29, 2026 For Q3 26

Estimate

$0.22

Actual

$0.28

Surprise

+26.53%

NovoCure Limited Ordinary Shares

Report Date

Oct 29, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.09

Surprise

+63.88%

FAQ

What were Annovis Bio, Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Annovis Bio, Inc. reported EPS of -$0.40, beating estimates by 13.49%, and revenue of $0.00, 0% as expectations.

How did the market react to Annovis Bio, Inc.'s Q2 2026 earnings?

The stock price moved up 3.35%, changed from $1.79 before the earnings release to $1.85 the day after.

When is Annovis Bio, Inc. expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for Annovis Bio, Inc.'s next earnings report?

Based on 5 analysts, Annovis Bio, Inc. is expected to report EPS of -$0.37 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.